Related Experiment Videos
Chemotherapy for invasive thymoma. A 13-year experience
A Fornasiero1, O Daniele, C Ghiotto
1Divisione di Oncologia Medica, Padova, Italy.
Cancer
|July 1, 1991
Summary
The ADOC chemotherapy regimen showed a high response rate for advanced thymoma patients. This treatment achieved significant complete remissions and warrants further investigation for adjuvant and neoadjuvant use.
Area of Science:
- Oncology
- Medical Research
Background:
- Thymoma is a rare tumor of the thymus gland.
- Advanced stages (III/IV) of invasive thymoma present significant treatment challenges.
Purpose of the Study:
- To evaluate the efficacy of the ADOC chemotherapy regimen in patients with advanced invasive thymoma.
- To assess response rates, duration of response, and survival outcomes.
Main Methods:
- A cohort of 37 patients with Stage III or IV invasive thymoma received the ADOC regimen (cisplatin, doxorubicin, vincristine, cyclophosphamide) monthly.
- Clinical response rates, including complete and partial remissions, were assessed.
- Duration of response and overall survival were analyzed.
Main Results:
- The overall clinical response rate was 91.8%, with 43% achieving complete remission.
- Median duration of response was 12 months, and median survival was 15 months.
- No life-threatening side effects were observed during the study.
Conclusions:
- The ADOC regimen demonstrates high efficacy in treating advanced invasive thymoma.
- The study suggests ADOC chemotherapy is a promising option for adjuvant and neoadjuvant treatment of thymoma.